title: Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor.
abstract: BACKGROUND
  The assessment of treatment efficacy in nonsmall cell lung cancer (NSCLC) is limited by the lack of a clear association between clinical response and survival. The prognostic usefulness of treatment-induced tumor-marker declines in NSCLC has not been established. The authors investigated the prognostic significance of treatment-induced declination in tumor marker levels of carcinoembryonic antigen, CA 19-9, and CA 125 in a group of patients with NSCLC treated with a brief course of cisplatin-based chemotherapy.
  
  
  METHODS
  Eighty-three patients with NSCLC enrolled on 2 related treatment protocols had pretreatment tumor-marker determinations. Patients were restaged 10 to 12 weeks after study entry, and clinical and marker responses were determined.
  
  
  RESULTS
  Thirty-eight patients (46%) had elevated pretreatment tumor markers, 36 (42%) of whom were evaluable for both clinical and marker responses. Pretreatment, the latter 36 individuals had measurable or evaluable disease, and at least one elevated tumor marker (greater than twice normal); posttreatment, they had follow-up measurements of both parameters. Of the 36 patients, 8 had normalization of tumor marker levels, 13 had 50-99% marker level declination, and 15 had less than 50% or no declination. In the same group of 36 patients, there were, 1 patient with complete clinical response, 11 with partial response, 19 with stable disease, and 5 with progressive disease. Marker responses occurred with equal frequency in clinical responders and nonresponders. There was no association between clinical response and survival, but there was a strong association between marker response and survival.
  
  
  CONCLUSIONS
  In patients with nonsmall cell lung cancer with elevated pretreatment tumor marker levels, treatment-induced marker level declination can be a surrogate indicator for survival.
authors.affiliation: Columbus Community Clinical Oncology Program, Ohio, USA.
authors.forename: C H
authors.initials: CH
authors.lastname: Spiridonidis
authors.forename: L R
authors.initials: LR
authors.lastname: Laufman
authors.forename: K A
authors.initials: KA
authors.lastname: Stydnicki
authors.forename: J W
authors.initials: JW
authors.lastname: Noltimier
authors.forename: C C
authors.initials: CC
authors.lastname: Cho
authors.forename: D C
authors.initials: DC
authors.lastname: Young
authors.forename: W J
authors.initials: WJ
authors.lastname: Hicks
authors.forename: M L
authors.initials: ML
authors.lastname: Segal
authors.forename: J T
authors.initials: JT
authors.lastname: Guy
authors.forename: B L
authors.initials: BL
authors.lastname: Zidar
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor